Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

[Prospective study on comparing two methods: for dynamic monitoring of minimal residual disease in acute promyelocytic leukemia].

Zhang Y, Tian LP, Zhang Y, Duan MH, Qin XM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):50-3. doi: 10.7534/j.issn.1009-2137.2014.01.011. Chinese.

PMID:
24598650
2.

[Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia].

Wang YZ, Chang Y, Zhu HH, Qin YZ, Li JL, Fu JY, Li LD, Chen SS, Huang XJ, Lu DP, Liu YR.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Jun;14(3):427-32. Chinese.

PMID:
16800913
4.

[Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].

Sun NN, Gan SL, Sun H, Zhang QT, Liu YF, Xie XS.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):339-42. doi: 10.7534/j.issn.1009-2137.2013.02.016. Chinese.

PMID:
23628028
5.

Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission.

Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci G, Lo Coco F.

Blood. 1993 Dec 15;82(12):3556-9.

6.

[Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].

Liu YR, Wang H, Chang Y, Cheng YF, Fu JY, Zhang LP, Liu GL, Chen SS.

Zhonghua Xue Ye Xue Za Zhi. 2005 Jun;26(6):327-31. Chinese.

PMID:
16185473
7.

Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia.

Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell RP Jr, Miller WH Jr.

Blood. 2001 Nov 1;98(9):2651-6.

8.

PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation.

Perego RA, Marenco P, Bianchi C, Cairoli R, Urbano M, Nosari AM, Muti G, Morra E, Del Monte U.

Leukemia. 1996 Feb;10(2):207-12.

PMID:
8637228
9.

Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.

Santamaría C, Chillón MC, Fernández C, Martín-Jiménez P, Balanzategui A, García Sanz R, San Miguel JF, González MG.

Haematologica. 2007 Mar;92(3):315-22.

10.

Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.

Thörn I, Forestier E, Botling J, Thuresson B, Wasslavik C, Björklund E, Li A, Lindström-Eriksson E, Malec M, Grönlund E, Torikka K, Heldrup J, Abrahamsson J, Behrendtz M, Söderhäll S, Jacobsson S, Olofsson T, Porwit A, Lönnerholm G, Rosenquist R, Sundström C.

Br J Haematol. 2011 Mar;152(6):743-53. doi: 10.1111/j.1365-2141.2010.08456.x. Epub 2011 Jan 20.

PMID:
21250970
11.

Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia.

Koller E, Karlic H, Krieger O, Mistrik M, Michlmayr G, Gadner H, Lutz D, Heinz R, Pittermann E.

Ann Hematol. 1995 Feb;70(2):75-8.

PMID:
7880927
12.

Combined use of reverse transcriptase polymerase chain reaction and flow cytometry to study minimal residual disease in Philadelphia positive acute lymphoblastic leukemia.

Muñoz L, López O, Martino R, Brunet S, Bellido M, Rubiol E, Sierra J, Nomdedéu JF.

Haematologica. 2000 Jul;85(7):704-10.

13.

Diagnosis and follow-up of acute promyelocytic leukemia by detection of PML-RAR alpha gene rearrangement.

Gau JP, Young JH, Lin TH, Yang YS.

Zhonghua Yi Xue Za Zhi (Taipei). 2000 Mar;63(3):175-81.

PMID:
10746412
14.

Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F.

Blood. 1998 Aug 1;92(3):784-9.

15.

[Detection of minimal residual disease in Ph+/bcr-abl+ acute lymphoblast leukemia by cytogenetic analysis, nested-PCR and flow cytometry].

Xue F, Dong ZR, Zhang B, Gao LX.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003 Aug;11(4):372-5. Chinese.

PMID:
12962565
16.

Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.

Chendamarai E, Balasubramanian P, George B, Viswabandya A, Abraham A, Ahmed R, Alex AA, Ganesan S, Lakshmi KM, Sitaram U, Nair SC, Chandy M, Janet NB, Srivastava VM, Srivastava A, Mathews V.

Blood. 2012 Apr 12;119(15):3413-9. doi: 10.1182/blood-2011-11-393264. Epub 2012 Feb 28.

17.

[Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].

Tong CR, Wang H, Yang JF, Lin YH, Zhang X, Zhao J, Fei XH, Gu JY, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2011 Nov;32(11):748-51. Chinese.

PMID:
22339910
18.

Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.

Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A, Scholten C, Thalhammer-Scherrer R, Brugger S, Keil F, Schwarzinger I, Haas OA, Lechner K, Jaeger U.

J Clin Oncol. 1998 Apr;16(4):1519-25.

PMID:
9552061
19.

[Clinical significance for minimal residual disease detection by 4 color flow cytometry in adult and childhood B lineage acute lymphoblastic leukemia].

Liu YR, Zhang LP, Chang Y, Cheng YF, Fu JY, Li LD, Wang H, Liu GL, Chen SS, Huang XJ, Lu DP.

Zhonghua Xue Ye Xue Za Zhi. 2006 May;27(5):302-5. Chinese.

PMID:
16875577
20.

The PML-RAR alpha transcript in long-term follow-up of acute promyelocytic leukemia patients.

Gameiro P, Vieira S, Carrara P, Silva AL, Diamond J, Botelho de Sousa A, Mehta AB, Prentice HG, Guimarães JE, Hoffbrand AV, Foroni L, Parreira A.

Haematologica. 2001 Jun;86(6):577-85.

Items per page

Supplemental Content

Write to the Help Desk